Safety and Efficacy of Adalimumab for Moderate to Severe Crohn's Disease in Children

2012/05/02 by Jeffrey S. Hyams, Anne M. Griffiths, Anne Griffiths +14 · 25 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #Inflammatory Bowel Disease #Rheumatoid Arthritis Research and Therapies #Pregnancy and Medication Impact

paper · pdf · doi:10.1053/j.gastro.2012.04.046

Citations

• Induction and Maintenance Infliximab Therapy for the Treatment of Moderate-to-Severe Crohn’s Disease in Children

Cited by

• Non-drug costs associated with outpatient infliximab administration in pediatric inflammatory bowel disease. [europepmc]
• Balancing and communicating the risks and benefits of biologics in pediatric inflammatory bowel disease. [europepmc]
• Inflammatory Bowel Disease in Children and Adolescents. [europepmc]
• Management of Crohn's disease. [europepmc]
• Systemic Treatment of Pediatric Psoriasis: A Review. [europepmc]
• Growth and Adult Height in Patients with Crohn's Disease Treated with Anti-Tumor Necrosis Factor α Antibodies. [europepmc]
• Diagnosis and management of inflammatory bowel disease in children. [europepmc]
• Early Infliximab Yields Superior Long-Term Effects on Linear Growth in Pediatric Crohn's Disease Patients. [europepmc]
• Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors. [europepmc]
• Adalimumab Reduces Extraintestinal Manifestations in Patients with Crohn's Disease: A Pooled Analysis of 11 Clinical Studies. [europepmc]
• Efficacy of Adalimumab for Treatment of Perianal Fistula in Children with Moderately to Severely Active Crohn's Disease: Results from IMAgINE 1 and IMAgINE 2. [europepmc]
• The Continental Divide: Anti-TNF Use in Pediatric IBD Is Different in North America Compared to Other Parts of the World. [europepmc]
• Vedolizumab use after failure of TNF-α antagonists in children and adolescents with inflammatory bowel disease. [europepmc]
• A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease. [europepmc]
• Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn's Disease. [europepmc]
• Elevated Pretreatment Plasma Oncostatin M Is Associated With Poor Biochemical Response to Infliximab. [europepmc]
• Adalimumab for induction of remission in Crohn's disease. [europepmc]
• Long-Term Efficacy of Anti-Tumor Necrosis Factor Agents in Pediatric Luminal Crohn's Disease: A Systematic Review of Real-World Evidence Studies. [europepmc]
• Favorable Outcomes and Anti-TNF Durability After Addition of an Immunomodulator for Anti-Drug Antibodies in Pediatric IBD Patients. [europepmc]
• The Treatment of Pediatric Inflammatory Bowel Disease with Biologic Therapies. [europepmc]
• Growth and Puberty in Children with Inflammatory Bowel Diseases. [europepmc]
• Positioning Biologic Therapies in the Management of Pediatric Inflammatory Bowel Disease. [europepmc]
• Advances in Therapeutic Drug Monitoring in Biologic Therapies for Pediatric Inflammatory Bowel Disease. [europepmc]
• Inflammatory Bowel Disease: Clinical Diagnosis and Pharmaceutical Management. [europepmc]
• Precision Dosing of Anti-TNF Therapy in Pediatric Inflammatory Bowel Disease. [europepmc]